Breaking News

Valeant Recalls Lot of Virazole

Observed sterility issue found during testing at 12 months

Valeant Pharmaceuticals North America LLC  has issued a voluntarily recall of one lot of Virazole (ribavirin powder for solution), 100mL, 6g Vial, 4-pack to the Hospital level. The product has been found to have an observed sterility issue during testing at 12 months. All other lots are not affected by this recall.

Virazole is indicated for the treatment of hospitalized infants and children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Valeant has not received reports of adverse events or injuries related to this recall.

Virazole is packaged in 100mL, 6g Vial, 4-pack NDC 00187-0007-14. The affected Virazole lot is Lot No. 340353F with an expiration date of Oct-2018. Virazole was distributed in the U.S. and Australia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters